BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Metastatic Castration-Resistant Prostate Cancer readouts · As
 setMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Metastatic Castration
 -Resistant Prostate Cancer\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03903835-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03903835)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: ProBio: A Biomarker Driven Study in Patients Wi
 th Metastatic Prostate Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480110-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06480110)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Ebastine in Combination With Docetaxel as a T
 reatment for Castration-resistant Metastatic Prostate Cancer\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06480110
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06402331-11154@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Zadavotide guraxetan: Phase 2 readout est. (NCT06402331)
DESCRIPTION:Zadavotide guraxetan\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSM
 A-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstima
 ted primary completion: 23 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06402331
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691804-9052@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT04691804)
DESCRIPTION:Fluzoparib\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Multicenter\, Randomized\, Double-Blind\, Placebo-Contr
 olled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and
  Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatme
 nt in Patients With Metastatic Castration-Resistant Prostate Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04691804
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253262-2060@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rucaparib: Phase 1/2 readout est. (NCT04253262)
DESCRIPTION:Rucaparib\, phase 1/2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Copanlisib Combined With Rucaparib in Patient
 s With Metastatic Castration-resistant Prostate Cancer\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rucaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04253262
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015622-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04015622)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: PROstate Cancer TReatment Optimization Via Anal
 ysis of Circulating Tumour DNA\nEstimated primary completion: 31 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04015622
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-2028@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Me
 tastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06909825
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-11154@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zadavotide guraxetan: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Zadavotide guraxetan\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Pati
 ents With Metastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimat
 ed primary completion: May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06909825
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047118-10762@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT07047118)
DESCRIPTION:Luxdegalutamide\, phase 2\, Metastatic Castration-Resistant Pro
 state Cancer.\nStudy: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (1
 77Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resista
 nt Prostate Cancer (mCRPC)\nEstimated primary completion: 16 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/luxdegalutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047118
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629779-7732@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06629779)
DESCRIPTION:Mevrometostat\, phase 3\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: A Study to Learn How PF-06821497 (Mevrometostat) Works
  in Men With Metastatic Castration-resistant Prostate Cancer.\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/mevrometostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06629779
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-2028@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination Therapies in
  Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
 \nEstimated primary completion: 22 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination 
 Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/
 KEYNOTE-365)\nEstimated primary completion: 22 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971211-9052@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT06971211)
DESCRIPTION:Fluzoparib\, phase 2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Radiotherapy Combined With Fluzopanib and Abiraterone Ace
 tate Tablets (II) Treatment for mCRPC\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fluzopari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 971211
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07225946)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Doc
 etaxel in Participants With Metastatic Castration-Resistant Prostate Cance
 r\nEstimated primary completion: 19 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-11218@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07225946)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Docetaxel in 
 Participants With Metastatic Castration-Resistant Prostate Cancer\nEstimat
 ed primary completion: 19 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520345-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06520345)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: The Study of 177Lu-TLX591 Plus SOC Versus SOC A
 lone in Patients With mCRPC (ProstACT Global)\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06520345
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311694-11070@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4357: Phase 3 readout est. (NCT07311694)
DESCRIPTION:HRS-4357\, phase 3\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Phase III Study Comparing HRS-4357 With Novel Androgen Re
 ceptor Pathway Inhibitors in Patients With Progressive\, PSMA-Positive Met
 astatic Castration-Resistant Prostate Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-
 4357#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07311694
URL:https://assetmemo.bio/drug/hrs-4357#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-2028@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olaparib: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: Ceralasertib (AZD6738) Alone and in Combination With Olapar
 ib or Durvalumab in Patients With Solid Tumors\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ol
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03682289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-11235@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Opevesostat\, phase 3\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Opevesostat (MK-5684) Versus Alternative Next
 -generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prosta
 te Cancer (mCRPC) Post One NHA (MK-5684-004)\nEstimated primary completion
 : 10 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/opeves
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06136650
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164443-11218@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280818
DTEND;VALUE=DATE:20280819
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07164443)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With or Without JNJ-87189401 Versus
  Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mC
 RPC)\nEstimated primary completion: 18 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07164443
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641855-2028@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Olaparib: Phase 2/3 readout est. (NCT07641855)
DESCRIPTION:Olaparib\, phase 2/3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of BL-B01D1 Combination Therapy in Patients With 
 Metastatic Castration-resistant Prostate Cancer\nEstimated primary complet
 ion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 laparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07641855
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-2028@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684
 )-Based Treatment Combinations or Opevesostat Alone in Participants With M
 etastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nEsti
 mated primary completion: 15 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesos
 tat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Partici
 pants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-568
 4-01A)\nEstimated primary completion: 15 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-11235@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Opevesostat: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Opevesostat\, phase 1/2\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5
 684)-Based Treatment Combinations or Opevesostat Alone in Participants Wit
 h Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nE
 stimated primary completion: 15 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/opevesostat#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844383-2243@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Talazoparib: Phase 2 readout est. (NCT06844383)
DESCRIPTION:Talazoparib\, phase 2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Talazoparib With or Without Enzalutamide in P
 eople With Prostate Cancer Who Have Previously Received Abiraterone Acetat
 e or Darolutamide\nEstimated primary completion: March 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06844383
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871435-11218@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pasritamig: Phase 1/2 readout est. (NCT07871435)
DESCRIPTION:Pasritamig\, phase 1/2\, Metastatic Castration-Resistant Prosta
 te Cancer.\nStudy: GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasrita
 mig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRP
 C) (JET-201)\nEstimated primary completion: 31 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07871435
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611110-11154@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Zadavotide guraxetan: Phase 3 readout est. (NCT07611110)
DESCRIPTION:Zadavotide guraxetan\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: AZD2265 Compared With Standard of Care in PSMA-
 positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)\nEsti
 mated primary completion: 4 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07611110
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07698535-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290705
DTEND;VALUE=DATE:20290706
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07698535)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: Measuring Circulating Tumor Deoxyribonucleic Ac
 id Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation 
 in Patients With Metastatic Castration-Resistant Prostate Cancer\, DYNAMO 
 Trial\nEstimated primary completion: 5 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07698535
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365995-2414@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Elfetabart drozuntecan: Phase 3 readout est. (NCT07365995)
DESCRIPTION:Elfetabart drozuntecan\, phase 3\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: A Phase III Trial of BNT324 Versus Docetaxel 
 in Metastatic Castration-resistant Prostate Cancer\nEstimated primary comp
 letion: February 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07365995
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-11235@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Opevesostat: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Opevesostat\, phase 1/2\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzuma
 b Tirumotecan to Treat Prostate Cancer (MK-2870-01A)\nEstimated primary co
 mpletion: 29 June 2032. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/opevesostat#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07908524
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667400-9029@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20361001
DTEND;VALUE=DATE:20361002
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07667400)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Docetaxel and SX-682 in Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma\, Salivary Gland Carcinoma\, and Adv
 anced Prostate Cancer\nEstimated primary completion: 1 October 2036. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07667400
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
